Wnt family member 5A (Wnt5a)

Wnt family member 5A (Wnt5a) is a secreted, lipid-modified glycoprotein that belongs to the Wnt family of signaling molecules, which are essential regulators of development and cell fate[1][2][3][4]. Wnt5a primarily signals through the noncanonical (β-catenin-independent) pathways by binding to receptors such as Frizzled (FZD), ROR1, ROR2, RYK, and PTK7, although it can also modulate canonical (β-catenin-dependent) Wnt signaling depending on receptor context[1][6][7]. Wnt5a controls cell migration, adhesion, polarity, and differentiation, and is vital for embryonic development, including skeletal and organ formation[1][2][4][6]. Mutations in the human WNT5A gene cause Robinow syndrome, which leads to skeletal and organ developmental abnormalities[4]. Aberrant Wnt5a expression or signaling is implicated in cancer (acting as either a tumor suppressor or promoter depending on context), as well as other tissue pathologies[3][4]. There are currently no approved drugs that directly target Wnt5a, but its signaling pathways are being explored as therapeutic targets[3][6]. Wnt5a expression may serve as a biomarker for disease progression or patient stratification in certain cancers[4]. Extensive safety concerns exist due to its fundamental roles in development and tissue maintenance[1][3].

Other names

WNT-5A proteinwingless-type MMTV integration site family member 5AhWNT5Awingless-type MMTV integration site family, member 5A

Most drugs and research tool compounds modulating Wnt5a act by inhibiting or activating its downstream signaling pathways (such as targeting Wnt5a–Ror2 signaling or interfering with receptor–ligand interactions)[6][3]. Antibodies or antagonists can block Wnt5a binding to its receptors.